<div class="article-image">
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-22-01-2026-shutterstock_2637269043-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-22-01-2026-shutterstock_2637269043-430x241.jpg"/>
                                    
                                    <figcaption>J&amp;J forecasts 2026 sales of $100.5bn and adjusted EPS of $11.53 at the midpoint. Credit: PixelBiss / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Johnson &amp; Johnson (J&amp;J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.</p>



<p>For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03.</p><div class="mpu-ad-container">
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div class="in-article-premium-insights mobile-useragent-scalar"><div class="cell large-2 sidebar-scalar mobile-only">
                   <div class="gdm-widget gdm-recommended-reports gdm-pi-recommended-reports gdm-orange-banner recommended-whitepapers"><h3>Go deeper with GlobalData</h3><ul><li><div class="cell small-2"><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div class="cell small-10 details"><div class="category">Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>United Kingdom (UK) - Healthcare, Regulatory and Reimbursement Land... </h4></div> </li></ul> <div class="about-premium-insights">
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The diluted earnings per share (EPS) for Q4 2025 stood at $2.10, up from $1.41 in Q4 2024, reflecting a 48.9% growth.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Additionally, the adjusted net earnings were reported at $6.1bn, up by 21.5% from $4.94bn in the same period of the prior year. Adjusted diluted EPS increased to $2.46 from the previous year’s $2.04, translating to a 20.6% growth.</p>



<p>Throughout the year, significant innovations included approvals for Caplyta in treating major depressive disorder and Rybrevant Faspro plus Lazcluze for non-small cell lung cancer.</p>



<p>J&amp;J also announced its guidance for 2026, forecasting estimated reported sales of $100.5bn and an adjusted EPS of $11.53 at the midpoint.</p><div class="gdm-company-profile-unit"> 
                         <div class="gdm-company-profile-unit__profile-container">


            <div class="gdm-company-profile-unit__image-container report-cover" style="width: auto; height: auto">

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div class="gdm-company-profile-unit__form-container">

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper" class="gdm-company-profile-unit__form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Operational sales of the global innovative medicine sector increased 5.3%, bolstered by products such as Erleada, Darzalex, Carvykti in oncology, and Tremfya in immunology, among others.</p>



<p>Medtech also saw a worldwide operational sales increase of 5.4%, driven mainly by electrophysiology products and Abiomed in cardiovascular and wound closure products in general surgery.</p><div id="slot-two"></div>



<p>J&amp;J chairman and CEO Joaquin Duato said: “2025 was a catapult year for Johnson &amp; Johnson, fuelled by the strongest portfolio and pipeline in our history.</p>



<p>“Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: oncology, immunology, neuroscience, cardiovascular, surgery, and vision. In each of these important areas, our leadership is expanding, driven by game-changing science and technology.”</p>



<p>In December 2025, J&amp;J completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.</p>
<div id="slot-three"></div><p></p>



<div class="grid-container">
    
</div>




<p>Johnson & Johnson reported a 9.1% increase in Q4 2025 sales, with full-year sales growing by 6% to $94.2bn. Q4 diluted EPS rose to $2.10, a 48.9% increase from Q4 2024. Adjusted net earnings reached $6.1bn, up 21.5%. The company forecasts 2026 sales of $100.5bn and adjusted EPS of $11.53. Key innovations included approvals for Caplyta and Rybrevant. J&J also acquired Halda Therapeutics for $3.05bn. CEO Joaquin Duato highlighted 2025 as a transformative year for the company, driven by medical innovation across key sectors.</p>

Pharmaceutical Technology

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

SPDR S&P Biotech

iShares US Medical Devices

Health Care Select Sector SPDR

Pelthos Therapeutics

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Johnson & Johnson reports 9.1% increase in sales for Q4 2025